** Shares of women’s health firm Daré Bioscience DARE.O rise 88% to $4.72
** Stock set for best day in over 5 years, if gains hold
** Co says its medical device, Ovaprene, showed a pregnancy rate of about 9% among participants, in an ongoing late-stage study, in line with previous results
** Ovaprene is an investigational, hormone-free, monthly intravaginal device to prevent pregnancy
** An independent safety board reviewed the data and recommended the study continue without changes, co says
** Vaginal odor was the main side effect, leading 17% of participants to leave the study
** Ovaprene works by releasing a non-hormonal agent that slows sperm and uses a polymer barrier to block them from reaching the cervix
** Including session moves, stock up 50% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.